News

New Patent for Caretaker Medical

Caretaker Medical has received issuance of a new Patent by the United States Patent and Trademark Office (USPTO) for self-calibrating systems for blood pressure wave form analysis and diagnostics, U.S. Patent No. 11,207,034, further strengthening the Company’s intellectual property position and coverage for the Company’s medical-grade continuous digital blood pressure and vital sign monitoring system.

“We are pleased to announce this new patent that is especially important for patient care as it enables ultra-fast, 30-second auto-calibration of arterial blood pressure, which is an essential measurement for cardiovascular health. This provides a big advantage over existing continuous blood pressure monitoring systems that require additional arm cuff calibration measurements, which add costly delays to set up time and patient care,” commented Jeff Pompeo, President and Chief Executive Officer of Caretaker Medical.

Caretaker Medical, a pioneer in wireless “beat-by-beat” hemodynamic monitoring technology, now has six issued patents in the U.S., Europe, and Asia, adding to the long-term value of our medical-grade VitalStream™ continuous patient monitoring system.

Learn more about Caretaker Medical here.

Recent News

09/30/2026

Activation Capital Recognizes President Michael Rao’s 17 Years of Leadership as Authority Board Chair, Names Paul Nolde as New Chair

Activation Capital, the operating name of the Virginia Biotechnology Research Partnership Authority, today announced the election of Paul Nolde as chair of the Authority Board, succeeding Virginia Commonwealth University President Michael Rao, Ph.D., who has served as chair since 2009. Rao will remain an active member of the board, continuing his longstanding support of Activation …

09/22/2026

ATCC to Lead Lifecycle Management of Military Medical Countermeasures Under 10-Year Department of War Contract

ATCC has been awarded a 10-year Department of War (DOW) contract to coordinate lifecycle management of medical countermeasures (MCMs) developed to protect U.S. military personnel from chemical and biological threats. Under this contract, ATCC supports the mission of the Rapid Access to Products in Development (RAPID) program to enable MCM preparedness against chemical and biological …

09/22/2026

Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to QRX003 for the treatment of Peeling Skin Syndrome (PSS). QRX003 is an investigational topical serine protease inhibitor lotion. …